1.Research progress on hepatitis C virus entry receptors.
Chinese Journal of Hepatology 2011;19(11):877-880
3.Infection of tupaia hepatocytes with hepatitis C virus in vitro.
Xi-ping ZHAO ; Zhan-fei TIAN ; Yi-chun CHEN ; Chun YANG ; De-ying TIAN ; Dong-liang YANG ; Lian-jie HAO
Chinese Journal of Hepatology 2005;13(11):805-807
OBJECTIVETupaia belangeri (tree shrew) has a close phylogenetic relationship with primates and has been shown to be susceptible to a variety of human viruses. This study was conducted to investigate whether or not hepatitis C virus (HCV) could infect primary tupaia hepatocytes (PTHs) in vitro.
METHODSSerum-derived HCV was cultivated with PTHs, and then positive and negative strand HCV RNA in PTHs, as well as the encapsidated HCV RNA in the culture medium were detected to evaluate the infection. Virus from the culture medium of the infected PTHs was passed to naïve PTHs, and the quasispecies of HCV were compared among the inoculum and PTHs after infection and passage.
RESULTSBoth positive and negative strand HCV RNA were detected in PTHs after infection. The negative strand RNA was detectable from day 5 to day 10 after infection, while the positive strand RNA was positive up to day 14. HCV RNA, which was RNase resistant, could be detected from the culture medium of the infected PTHs from day 3 to day 14. Production of infectious virons of PTH were demonstrated by passage HCV to naïve PTHs. Compared analysis of HCV quasispecies after infection and passage showed that PTHs were selectively infected with defined HCV quasispecies, and new quasispecies emerged in PTHs after passage.
CONCLUSIONThe present study strongly indicates that PTHs could be infected by HCV and support HCV replication in vitro. Our results would be helpful for the establishment of a tupaia model of HCV infection.
Animals ; Cells, Cultured ; Hepacivirus ; pathogenicity ; physiology ; Hepatocytes ; virology ; Tupaia ; Virus Replication
6.Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients.
Tatsuo KANDA ; Osamu YOKOSUKA ; Masao OMATA
Chinese Medical Journal 2013;126(23):4568-4574
OBJECTIVETo review the updated research on direct antiviral agents (DAAs)-including regimens for hepatitis C virus (HCV), and focus on "difficult-to-treat" HCV-infected patients.
DATA SOURCESThe literature concerning DAAs and hepatitis C cited in this review was collected from PubMed and Google Scholar databases published in English up to July 2013.
STUDY SELECTIONData from published articles regarding HCV and DAAs in clinical trials and in clinical use were identified and reviewed.
RESULTSIt was recognized that some "difficult-to-treat" patients would still exist, even though stronger treatments using such as DAAs, including telaprevir and boceprevir, which lead to higher sustained virological response rates, are available. Such patients include those with advanced fibrosis/cirrhosis, elderly persons, children, HCV-human immunodeficiency virus co-infected patients, HCV-infected recipients, and so on.
CONCLUSIONSCertain "difficult-to-treat" patients would still exist, even though stronger treatment is available. Although evidence from clinical trials is still lacking, interferon-sparing regimens could have stronger effects for eradicating HCV in such cases.
Antiviral Agents ; pharmacology ; therapeutic use ; Hepacivirus ; drug effects ; pathogenicity ; Hepatitis C, Chronic ; drug therapy ; Humans
7.Proapoptotic and pronecrosis effect of different truncated hepatitis C virus core proteins.
Xue-bing YAN ; Zhi CHEN ; Dong-hui LUO ; Xiao-yan XU ; Wei WU ; Lin-fu ZHOU
Journal of Zhejiang University. Science. B 2005;6(4):295-300
OBJECTIVETo study the roles of different truncated hepatitis C virus (HCV) core proteins (CORE) in the pathogenesis of HCV persistent infection and hepatocellular carcinoma (HCC) and to assess intracellular localization in transiently transfected cells.
METHODSSeven truncated GFP (green fluorescent protein)-CORE fusion protein expression plasmids were constructed, which contained HCV CORE sequences derived from tumor tissues (BT) and non-tumor tissues (BNT) from one patient infected with HCV. Amino acid (aa) lengths were BT: 1-172 aa, 1-126 aa, 1-58 aa, 59-126 aa, 127-172 aa; BNT: 1-172 aa and C191: 1-172 aa respectively. Subcellular localization of CORE-GFP was analyzed by con-focal laser scanning microscope. Apoptosis and necrosis were quantified by flow cytometry.
RESULTSDifferent truncated CORE-GFP localized mainly in the cytoplasm, but nuclear staining was also observed. HCV CORE could induce apoptosis and necrosis, and different truncated COREs could induce cell apoptosis and necrosis at different levels. Among the same length 1-172 aa of BT, BNT and C191, the cell apoptosis and necrosis percentage of BT is highest, and C191 is the lowest (BT>BNT>C191). To the different fragment COREs of BT, N-terminal of CORE induced apoptosis and necrosis higher, compared with that of C-terminal (1-172 aa>1-126 aa>1-58 aa>127-172 aa>59-126 aa).
CONCLUSIONThese results suggest HCV CORE could induce apoptosis and necrosis of cells, which might play an important role in the pathogenesis of HCV persistent infection and HCC and the different CORE domains of different HCV quasi-species might have some difference in their pathogenesis.
Apoptosis ; Cell Line, Tumor ; Hepacivirus ; genetics ; pathogenicity ; physiology ; Humans ; Necrosis ; virology ; Sequence Deletion ; genetics ; Viral Core Proteins ; chemistry ; genetics ; metabolism
8.Relationship between Hepatitis C Virus Infection and Iron Overload.
Chinese Medical Journal 2017;130(7):866-871
OBJECTIVEThe aim of this study was to summarize the interactions between hepatitis C virus (HCV) infection and iron overload, and to understand the mechanisms of iron overload in chronic hepatitis C (CHC) and the role iron plays in HCV life cycle.
DATA SOURCESThis review was based on data in articles published in the PubMed databases up to January 28, 2017, with the keywords "hepatitis C virus", "iron overload", "iron metabolism", "hepcidin", "translation", and "replication".
STUDY SELECTIONArticles related to iron metabolism, iron overload in patients with CHC, or the effects of iron on HCV life cycle were selected for the review.
RESULTSIron overload is common in patients with CHC. The mechanisms involve decreased hepcidin levels caused by HCV through signal transducer and activator of transcription 3, mitogen-activated protein kinase, or bone morphogenetic protein/SMAD signaling pathways, and the altered expression of other iron-metabolism-related genes. Some studies found that iron increases HCV replication, while other studies found the opposite result. Most of the studies suggest the positive role of iron on HCV translation, the mechanisms of which involve increased expression levels of factors associated with HCV internal ribosome entry site-dependent translation, such as eukaryotic initiation factor 3 and La protein.
CONCLUSIONThe growing literature demonstrates that CHC leads to iron overload, and iron affects the HCV life cycle in turn. Further research should be conducted to clarify the mechanism involved in the complicated interaction between iron and HCV.
Female ; Hepacivirus ; pathogenicity ; Hepatitis C ; complications ; metabolism ; Hepcidins ; metabolism ; Humans ; Iron Overload ; etiology ; metabolism ; virology ; Male ; Signal Transduction
9.A Case of Acute Disseminated Encephalomyelitis Associated with Hepatitis C Virus Infection.
Jae Eun SIM ; Jun Bum LEE ; Yu Na CHO ; Sang Hyun SUH ; Ja Kyung KIM ; Kyung Yul LEE
Yonsei Medical Journal 2012;53(4):856-858
Acute disseminated encephalomyelitis (ADEM) is a monophasic autoimmune demyelinating disease of the central nervous system, which typically follows acute viral or bacterial infection or vaccination. We report a case of ADEM associated with hepatitis C virus (HCV) infection with positive serum and cerebrospinal fluid (CSF) anti-HCV antibody. After steroid treatment, neurologic symptoms were improved. Virus triggers autoimmunity or direct viral invasion plays a part in the genesis of ADEM. This is the first reported case of ADEM with anti-HCV antibody in the CSF.
Encephalomyelitis, Acute Disseminated/*diagnosis/drug therapy/etiology/virology
;
Female
;
Hepacivirus/pathogenicity
;
Hepatitis C/*complications
;
Humans
;
Methylprednisolone/therapeutic use
;
Middle Aged
10.Hepatitis C virus-induced hepatocellular carcinoma.
Nicolas GOOSSENS ; Yujin HOSHIDA
Clinical and Molecular Hepatology 2015;21(2):105-114
Hepatitis C virus (HCV) is a leading etiology of hepatocellular carcinoma (HCC). The interaction of HCV with its human host is complex and multilayered; stemming in part from the fact that HCV is a RNA virus with no ability to integrate in the host's genome. Direct and indirect mechanisms of HCV-induced HCC include activation of multiple host pathways such as liver fibrogenic pathways, cellular and survival pathways, interaction with the immune and metabolic systems. Host factors also play a major role in HCV-induced HCC as evidenced by genomic studies identifying polymorphisms in immune, metabolic, and growth signaling systems associated with increased risk of HCC. Despite highly effective direct-acting antiviral agents, the morbidity and incidence of liver-related complications of HCV, including HCC, is likely to persist in the near future. Clinical markers to selectively identify HCV subjects at higher risk of developing HCC have been reported however they require further validation, especially in subjects who have experienced sustained virological response. Molecular biomarkers allowing further refinement of HCC risk are starting to be implemented in clinical platforms, allowing objective stratification of risk and leading to individualized therapy and surveillance for HCV individuals. Another role for molecular biomarker-based stratification could be enrichment of HCC chemoprevention clinical trials leading to smaller sample size, shorter trial duration, and reduced costs.
Biomarkers, Tumor/genetics/metabolism
;
Carcinoma, Hepatocellular/*etiology
;
Hepacivirus/genetics/*pathogenicity
;
Hepatitis C/complications/pathology/virology
;
Humans
;
Liver Neoplasms/*etiology
;
Risk